Key Points – Lucid Diagnostics reported Q1 2026 EsoGuard test volume of 3,177 and revenue of $1.3 million, with volume still above its pre-Medicare target range despite a sequential decline from Q4. – Management said the company remains highly focused on a Medicare local…
verage determination, calling it the key near-term catalyst and expecting a positive outcome despite delays in the process. – Lucid strengthened its balance sheet with a public offering that added about $16.8 million, bringing pro forma cash to roughly $45 million and extending its runway well into 2027. – October’s 4 Best Penny Stocks: High-Risk, High-Reward Picks Lucid Diagnostics (NASDAQ:LUCD) reported first-quarter 2026 EsoGuard test volume above its pre-Medicare target range, while management said it continues to await a Medicare local coverage determination and is expanding efforts with the Department of Veterans Affairs, commercial payers and health systems. Chairman and Chief Executive Officer Dr
Lishan Aklog said the company performed 3,177 EsoGuard tests in the quarter and generated $1.3 million in revenue. He said revenue was down slightly in proportion to volume, which declined from the fourth quarter but remained above the company’s stated target range of 2,500 to 3,000 tests during the pre-Medicare period. Aklog said Lucid also strengthened its balance sheet through an underwritten public offering of common stock that netted about $16.8 million in proceeds.
He said the financing increased the company’s pro forma cash position to approximately $45 million at the end of the first quarter and extended its cash runway “well into 2027.” Medicare decision remains central focus Management repeatedly emphasized that Medicare coverage remains the company’s key near-term catalyst. Aklog said Lucid continues to have confidence in the Medicare local coverage determination, or LCD, process despite delays. “We continue to have our confidence that this is a near-term result really hasn’t wavered…